Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACYW versus Nimenrix immunogenicity and safety study in healthy adolescents
2020-001665-37Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of Meningococcal ACWY conjugate vaccine, Meningococcal polysaccharide vaccine group W-135, recombinant human papillomavirus 9-valent vaccine and Adacel Polio in meningococcal disease (2 arms), sponsored by Sanofi. Primary endpoints: Seroprotection against meningococcal serogroups A, C, W, and Y and Antibody titers to meningococcal serogroups A, C, W, and Y. Started Jan 2021; status: completed.
02
Drugs
Meningococcal ACWY conjugate vaccineMeningococcal polysaccharide vaccine group W-135recombinant human papillomavirus 9-valent vaccineAdacel Polio
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2020-001665-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001665-37.